PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33646450-11 2021 CONCLUSION: Our results indicate that GW0742 may serve as a candidate agent to mitigate cisplatin nephrotoxicity via inhibiting the mitochondrial apoptotic pathway considerably depending on PPAR-delta, without modulating autophagy. GW0742 38-44 peroxisome proliferator activator receptor delta Mus musculus 190-200 33646450-9 2021 The inhibitory effect of GW0742 on cisplatin-induced caspase-3 activation was significantly diminished by silencing of the PPAR-delta gene expression. GW0742 25-31 peroxisome proliferator activator receptor delta Mus musculus 123-133 15939051-0 2005 The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. GW0742 22-29 peroxisome proliferator activator receptor delta Mus musculus 4-13 15939051-4 2005 We demonstrate here that the PPARdelta agonist, GW0742X has potent anti-atherogenic activity in the LDLR(-/-) mouse, decreasing lesion area by up to 50%. GW0742 48-55 peroxisome proliferator activator receptor delta Mus musculus 29-38 14684157-6 2004 Palmitate oxidation rates were significantly increased in both neonatal and adult cardiomyocytes after treatment of a PPARdelta-selective ligand (GW0742). GW0742 146-152 peroxisome proliferator activator receptor delta Mus musculus 118-127 31635041-5 2019 24 mice were assigned to groups according to an 8-week exercise training program and/or an 8-week treatment with 3 mg/kg/day of GW0742, a PPARbeta/delta agonist. GW0742 128-134 peroxisome proliferator activator receptor delta Mus musculus 138-146 31008686-6 2019 In this study, the effects of GW0742 (a selective PPAR-delta agonist) on hippocampal synaptic transmission, plasticity, and spatial memory were investigated in the db/db mouse model of T2DM. GW0742 30-36 peroxisome proliferator activator receptor delta Mus musculus 50-60 29697010-2 2018 We hypothesized that the PPAR-beta/delta-agonist GW0742 improves long-term outcome after sepsis caused by cecal ligation and puncture (CLP). GW0742 49-55 peroxisome proliferator activator receptor delta Mus musculus 25-34 30453390-0 2019 PPARbeta/delta-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1DeltaE9 astrocytes. GW0742 23-29 peroxisome proliferator activator receptor delta Mus musculus 0-8 30453390-5 2019 The impairment was corrected by treatment with a synthetic peroxisome proliferator activated receptor delta (PPARbeta/delta) agonist GW0742 which acts to regulate an array of genes governing cellular metabolism. GW0742 133-139 peroxisome proliferator activator receptor delta Mus musculus 59-107 30453390-5 2019 The impairment was corrected by treatment with a synthetic peroxisome proliferator activated receptor delta (PPARbeta/delta) agonist GW0742 which acts to regulate an array of genes governing cellular metabolism. GW0742 133-139 peroxisome proliferator activator receptor delta Mus musculus 109-117 29580823-0 2018 GW0742 (PPAR-beta agonist) attenuates hepatic endoplasmic reticulum stress by improving hepatic energy metabolism in high-fat diet fed mice. GW0742 0-6 peroxisome proliferator activator receptor delta Mus musculus 8-17 29580823-3 2018 This study aimed to investigate the effects of GW0742 (PPAR-beta agonist) on hepatic energy metabolism and ER stress in a murine diet-induced obesity model. GW0742 47-53 peroxisome proliferator activator receptor delta Mus musculus 55-64 30227151-0 2018 The PPARdelta agonist GW0742 restores neuroimmune function by regulating Tim-3 and Th17/Treg-related signaling in the BTBR autistic mouse model. GW0742 22-28 peroxisome proliferator activator receptor delta Mus musculus 4-13 28242713-2 2017 We tested whether GW0742, a peroxisome proliferator activator receptor beta/delta (PPARbeta/delta) agonist, ameliorates disease activity and cardiovascular complications in a female mouse model of lupus. GW0742 18-24 peroxisome proliferator activator receptor delta Mus musculus 83-91 27939528-9 2017 Differential effects of GW0742 observed during the regeneration were associated with variations of PPARbeta pathway activity. GW0742 24-30 peroxisome proliferator activator receptor delta Mus musculus 99-107 28242713-9 2017 All these effects of GW0742 were inhibited by PPARbeta/delta blockade with GSK0660. GW0742 21-27 peroxisome proliferator activator receptor delta Mus musculus 46-54 27189971-9 2016 In conclusion, GW0742 exerted antihypertensive effects, restoring sympathetic tone and vascular structure and function in AngII-infused mice by PPARbeta activation in brain and vessels inhibiting AngII signaling as a result of RGS5 upregulation. GW0742 15-21 peroxisome proliferator activator receptor delta Mus musculus 144-152 27818230-0 2017 Effect of PPAR-beta/delta agonist GW0742 treatment in the acute phase response and blood-brain barrier permeability following brain injury. GW0742 34-40 peroxisome proliferator activator receptor delta Mus musculus 10-19 27818230-5 2017 In the present study, we determined for the first time, the effects of GW0742, a PPAR-beta/delta agonist on the APR following brain injury and assessed the effects on BBB permeability and tight junction integrity via claudin-5, occludin, and zona occludens-1 expression. GW0742 71-77 peroxisome proliferator activator receptor delta Mus musculus 81-90 27179975-5 2016 The PPARbeta/delta antagonist GSK0660 abolished all these in vivo and in vitro protective effects induced by GW0742. GW0742 109-115 peroxisome proliferator activator receptor delta Mus musculus 4-12 27179975-3 2016 In vivo, the PPARbeta/delta agonist GW0742 treatment prevented the LPS-induced reduction in aortic relaxation, the increase in vascular ROS production, the upregulation of NOX1, NOX2, p47(phox), and p22(phox) mRNA levels, and the endoplasmic reticulum (ER) stress markers in mice. GW0742 36-42 peroxisome proliferator activator receptor delta Mus musculus 13-21 26655383-2 2016 Molecular mechanisms were investigated using differentiated C2C12 myotubes treated with alpha-LA and/or PPARbeta agonist GW0742. GW0742 121-127 peroxisome proliferator activator receptor delta Mus musculus 104-112 26864581-0 2016 PPARdelta agonist GW0742 ameliorates Abeta1-42-induced hippocampal neurotoxicity in mice. GW0742 18-24 peroxisome proliferator activator receptor delta Mus musculus 0-9 26864581-3 2016 In the current study, the effect of GW0742, a selective PPARdelta agonist, on Abeta1-42-induced neurotoxicity was investigated in the hippocampus of mice. GW0742 36-42 peroxisome proliferator activator receptor delta Mus musculus 56-65 25662586-2 2015 In the current study, we determined the effects of the PPAR-beta/delta agonist GW0742 on HDL composition and the expression of liver HDL-related genes in mice and cultured human cells. GW0742 79-85 peroxisome proliferator activator receptor delta Mus musculus 55-64 26997622-3 2016 Balb/c mice were trained on a treadmill and administered both the AMPK activator AICAR and the PPARdelta agonist GW0742 for 4 weeks. GW0742 113-119 peroxisome proliferator activator receptor delta Mus musculus 95-104 26508837-3 2015 GW0742, a selective peroxisome proliferator-activated receptor (PPAR)-delta agonist, has been shown to ameliorate metabolic abnormalities including IR in skeletal muscle in mice fed high-fructose corn syrup. GW0742 0-6 peroxisome proliferator activator receptor delta Mus musculus 20-75 27150147-5 2016 Here, we demonstrate that treatment using a high-affinity PPARbeta/delta agonist, GW0742, reverses the lung tissue damage induced by elastase in emphysema-model mice and improves respiratory function. GW0742 82-88 peroxisome proliferator activator receptor delta Mus musculus 58-66 26253087-5 2015 The PPARbeta/delta antagonist GSK0660 abolished all of these protective effects induced by GW0742. GW0742 91-97 peroxisome proliferator activator receptor delta Mus musculus 4-12 25662586-6 2015 The GW0742-mediated effects on liver Pltp expression and serum enzyme activity were completely abolished in PPAR-beta/delta-deficient mice. GW0742 4-10 peroxisome proliferator activator receptor delta Mus musculus 108-117 25662586-8 2015 Collectively, our findings demonstrate a common transcriptional upregulation by GW0742-activated PPAR-beta/delta of Pltp expression in cultured cells and in mouse liver resulting in enhanced serum PLTP activity. GW0742 80-86 peroxisome proliferator activator receptor delta Mus musculus 97-106 25592770-6 2015 METHODS: 5XFAD mice were orally treated with the PPARdelta agonist GW0742 for 2 weeks. GW0742 67-73 peroxisome proliferator activator receptor delta Mus musculus 49-58 25592770-14 2015 CONCLUSIONS: This study demonstrates that GW0742 treatment has a prominent anti-inflammatory effect in 5XFAD mice and suggests that PPARdelta agonists may have therapeutic utility in treating AD. GW0742 42-48 peroxisome proliferator activator receptor delta Mus musculus 132-141 24814977-9 2014 Treatment of mouse AML12 hepatocytes with the PPARbeta agonist (GW0742) decreased (14)C-18:2,n-6 in TGs but did not affect beta-oxidation. GW0742 64-70 peroxisome proliferator activator receptor delta Mus musculus 46-54 23103566-7 2013 All of the above effects of HFCS-55 were attenuated by the specific PPAR-delta agonist GW0742. GW0742 87-93 peroxisome proliferator activator receptor delta Mus musculus 68-78 25006409-0 2013 The peroxisome proliferator-activated receptor beta/delta agonist GW0742 has direct protective effects on right heart hypertrophy. GW0742 66-72 peroxisome proliferator activator receptor delta Mus musculus 4-51 25006409-15 2013 In conclusion, the PPARbeta/delta agonist GW0742 has direct protective effects on the right heart in vivo. GW0742 42-48 peroxisome proliferator activator receptor delta Mus musculus 19-27 23500098-4 2013 In vitro administration of the PPARdelta antagonist GSK0660 (1 muM) increased the detrimental effect of 1-methyl-4-phenylpyridinium iodide (MPP+) on cell viability, which was reversed by co-treatment with agonist GW0742 (1 muM). GW0742 213-219 peroxisome proliferator activator receptor delta Mus musculus 31-40 23499837-0 2013 The PPARdelta agonist GW0742 inhibits neuroinflammation, but does not restore neurogenesis or prevent early delayed hippocampal-dependent cognitive impairment after whole-brain irradiation. GW0742 22-28 peroxisome proliferator activator receptor delta Mus musculus 4-13 23499837-3 2013 In this study, we determined if the peroxisomal proliferator-activated receptor (PPAR) delta agonist GW0742 can prevent radiation-induced brain injury in C57Bl/6 wild-type (WT) and PPARdelta knockout (KO) mice. GW0742 101-107 peroxisome proliferator activator receptor delta Mus musculus 181-190 23103566-8 2013 Thus, we demonstrate for the first time that the specific PPAR-delta agonist GW0742 attenuates the metabolic abnormalities and the renal dysfunction/inflammation caused by chronic HFCS-55 exposure by preventing upregulation of fructokinase (liver) and activation of the NLRP3 inflammasome (kidney). GW0742 77-83 peroxisome proliferator activator receptor delta Mus musculus 58-68 21685825-0 2012 GW0742, a high-affinity PPAR-delta agonist, mediates protection in an organotypic model of spinal cord damage. GW0742 0-6 peroxisome proliferator activator receptor delta Mus musculus 24-34 23861559-3 2013 This study aimed to investigate the signaling pathways activated in the gastrocnemius muscle by chronic administration of the selective PPAR- delta agonist, GW0742 (1 mg/kg/day for 16 weeks), in male C57Bl6/J mice treated for 30 weeks with high-fructose corn syrup (HFCS), the major sweetener in foods and soft-drinks (15% wt/vol in drinking water). GW0742 157-163 peroxisome proliferator activator receptor delta Mus musculus 136-147 23861559-6 2013 GW0742 administration induced PPAR- delta upregulation and improvement in glucose and lipid metabolism. GW0742 0-6 peroxisome proliferator activator receptor delta Mus musculus 30-41 22521259-0 2012 Peroxisome proliferator-activated receptor beta/delta agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice. GW0742 62-68 peroxisome proliferator activator receptor delta Mus musculus 0-47 21685825-2 2012 OBJECTIVE: To clarify the protective mechanism of PPAR-delta agonist GW0742 in the injured spinal cord using an in vitro model. GW0742 69-75 peroxisome proliferator activator receptor delta Mus musculus 50-60 21685825-10 2012 CONCLUSION: GW0742 reduces the cellular and molecular changes occurring in SCI by targeting different downstream pathways modulating PPAR-delta receptors. GW0742 12-18 peroxisome proliferator activator receptor delta Mus musculus 133-143 21765606-3 2011 Mice treated with copper and peroxisome proliferator-activated receptor beta/delta agonist GW0742 had significantly less body weight loss, less serum alanine aminotransferase increase, less tumor necrosis factor alpha, macrophage inflammatory protein-2 and 8-hydroxy-2"-deoxyguanosine upregulation than copper treated mice. GW0742 91-97 peroxisome proliferator activator receptor delta Mus musculus 29-76 21426320-5 2011 Plasma metabolic parameters were similar in wild-type and PPARdelta KI mice when fed chow or HFD, and following physiological (fasting) and pharmacological (GW0742 compound) activation of PPARdelta. GW0742 157-163 peroxisome proliferator activator receptor delta Mus musculus 188-197 21798999-5 2011 We report that PPARbeta activation with GW0742 induces a rapid (2 h) and sustained down-regulation of gamma3-AMPK expression both in mouse skeletal muscles and in culture myotubes. GW0742 40-46 peroxisome proliferator activator receptor delta Mus musculus 15-23 20407409-0 2010 GW0742, a high-affinity PPAR -beta/delta agonist, inhibits acute lung injury in mice. GW0742 0-6 peroxisome proliferator activator receptor delta Mus musculus 24-34 21159610-4 2010 Ligand activation of PPARbeta/delta with GW0742 caused a PPARbeta/delta-dependent delay in the onset of tumor formation. GW0742 41-47 peroxisome proliferator activator receptor delta Mus musculus 21-29 21159610-4 2010 Ligand activation of PPARbeta/delta with GW0742 caused a PPARbeta/delta-dependent delay in the onset of tumor formation. GW0742 41-47 peroxisome proliferator activator receptor delta Mus musculus 57-65 20709805-4 2010 We demonstrated that administration of GW0742, a specific PPARdelta ligand, provided beneficial effects to rats subjected to cecal ligation and puncture, as shown by reduced systemic release of pro-inflammatory cytokines and neutrophil infiltration in lung, liver, and cecum, when compared with vehicle treatment. GW0742 39-45 peroxisome proliferator activator receptor delta Mus musculus 58-67 20709805-8 2010 RNA silencing of PPARdelta abrogated the inhibitory effects of GW0742 on TNFalpha production. GW0742 63-69 peroxisome proliferator activator receptor delta Mus musculus 17-26 21244753-0 2010 GW0742, a high affinity PPAR-beta/delta agonist reduces lung inflammation induced by bleomycin instillation in mice. GW0742 0-6 peroxisome proliferator activator receptor delta Mus musculus 24-33 21244753-5 2010 Therefore, the aim of this study is to investigate the effects of GW0742, a synthetic high affinity PPAR beta/delta agonist, and its possible role in preventing the advance of inflammatory and apoptotic processes induced by bleomycin, that long-term leads to the appearance of pulmonary fibrosis. GW0742 66-72 peroxisome proliferator activator receptor delta Mus musculus 100-109 20430778-0 2010 GW0742, a selective PPAR-beta/delta agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury. GW0742 0-6 peroxisome proliferator activator receptor delta Mus musculus 20-29 20430778-6 2010 This study investigated the effects of GW0742, a potent and selective PPAR-beta/delta agonist, on tissue injury, caused in a mouse model of SAO shock. GW0742 39-45 peroxisome proliferator activator receptor delta Mus musculus 70-79 20693380-9 2010 All the observed beneficial effects of GW0742 were attenuated by the PPAR-beta/delta antagonist GSK0660. GW0742 39-45 peroxisome proliferator activator receptor delta Mus musculus 69-78 20176685-11 2010 30 min before treatment with GW0742) significantly blocked the effect of the PPAR-beta/delta agonist and thus abolished the protective effect. GW0742 29-35 peroxisome proliferator activator receptor delta Mus musculus 77-86 20407409-2 2010 The aim of this study was to investigate the effects of a high-affinity PPAR-beta/delta agonist, GW0742, in a mouse model of carrageenan (CAR)-induced pleurisy. GW0742 97-103 peroxisome proliferator activator receptor delta Mus musculus 72-81 20407409-7 2010 Thus, based on these findings, we propose that a PPAR-beta/delta agonist such as GW0742 may be useful in the treatment of various inflammatory diseases. GW0742 81-87 peroxisome proliferator activator receptor delta Mus musculus 49-58 19577614-4 2009 Cell culture experiments revealed that CACT mRNA abundance was higher in liver cells treated with either WY-14,643 or PPARdelta agonist GW0742, but not with PPARgamma agonist troglitazone (TGZ) than in control cells (P<0.05). GW0742 136-142 peroxisome proliferator activator receptor delta Mus musculus 118-127 19748995-7 2010 Interestingly, the combined treatment of GW0742 and nimesulide increased the efficacy of the decrease in papilloma multiplicity for 6 weeks in wild-type mice, but this effect was not found at later time points and was not found in similarly treated Pparbeta/delta-null mice. GW0742 41-47 peroxisome proliferator activator receptor delta Mus musculus 249-257 20167109-11 2010 The PPAR-beta/delta agonist, GW0742, at the dose of 0,3 mg/kg in 10% DMSO, also attenuated the multiple organ dysfunction syndrome caused by zymosan. GW0742 29-35 peroxisome proliferator activator receptor delta Mus musculus 4-13 20001953-4 2010 We show that effects of GW0742 are mediated through PPARdelta since no amelioration of EAE clinical scores was observed in PPARdelta-null mice. GW0742 24-30 peroxisome proliferator activator receptor delta Mus musculus 52-61 17631136-9 2007 In contrast to the beneficial effect of fenofibrate, the PPARdelta ligand GW0742 accelerated the onset of colitis in IL-10(-/-) mice. GW0742 74-80 peroxisome proliferator activator receptor delta Mus musculus 57-66 18593727-0 2008 PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. GW0742 115-121 peroxisome proliferator activator receptor delta Mus musculus 22-32 18622687-0 2008 Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta/delta ligand GW0742. GW0742 123-129 peroxisome proliferator activator receptor delta Mus musculus 101-109 18622687-1 2008 OBJECTIVE: To define the anti-inflammatory effects of PPARbeta/delta activation by use of the selective PPARbeta/delta ligand (GW0742) in a model of lipopolysaccharide (LPS)-induced pulmonary inflammation. GW0742 127-133 peroxisome proliferator activator receptor delta Mus musculus 54-62 18622687-1 2008 OBJECTIVE: To define the anti-inflammatory effects of PPARbeta/delta activation by use of the selective PPARbeta/delta ligand (GW0742) in a model of lipopolysaccharide (LPS)-induced pulmonary inflammation. GW0742 127-133 peroxisome proliferator activator receptor delta Mus musculus 104-112 18622687-2 2008 METHODS: Male BALB/c mice were pretreated for three days with the PPARbeta/delta agonist, GW0742, prior to induction of LPS-mediated pulmonary inflammation. GW0742 90-96 peroxisome proliferator activator receptor delta Mus musculus 66-74 20169010-3 2009 PPARdelta agonist GW0742 (10 mg/kg per day) did not change 3H-tracer plasma appearance, but increased fecal 3H-free sterols excretion by 103% ( p < 0.005) over 48 hours. GW0742 18-24 peroxisome proliferator activator receptor delta Mus musculus 0-9 18622026-5 2008 GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice. GW0742 0-6 peroxisome proliferator activator receptor delta Mus musculus 231-239 18627005-9 2008 Knockdown of endogenous Insig-1 attenuated the suppressive effect of GW0742 on SREBP-1 and its target genes, indicating PPARdelta inhibited SREBP-1 activation via induction of Insig-1. GW0742 69-75 peroxisome proliferator activator receptor delta Mus musculus 120-129 17893232-6 2008 Inhibition of COX2 by nimesulide attenuated colon cancer and ligand activation of PPARbeta/delta by GW0742 had inhibitory effects. GW0742 100-106 peroxisome proliferator activator receptor delta Mus musculus 82-90 16618765-3 2006 This hypothesis was examined by treating wild-type (Pparb+/+) and Pparb-/- with azoxymethane, coupled with a highly specific PPARbeta ligand, GW0742. GW0742 142-148 peroxisome proliferator activator receptor delta Mus musculus 125-133 16021179-2 2006 By using of a highly specific ligand (GW0742) and the PPARbeta-null mouse model, activation of PPARbeta was found to selectively induce keratinocyte terminal differentiation and inhibit keratinocyte proliferation. GW0742 38-44 peroxisome proliferator activator receptor delta Mus musculus 95-103 16098614-3 2005 We show that oral administration of the selective PPARdelta agonist GW0742 reduced clinical symptoms in C57BL/6 mice that had been immunized with encephalitogenic myelin oligodendrocyte glycoprotein (MOG) peptide. GW0742 68-74 peroxisome proliferator activator receptor delta Mus musculus 50-59